Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Size (2024 - 2029)

The market size for SGLT2 inhibitors, a class of medications used primarily for managing type 2 diabetes, is projected to experience significant growth over the forecast period. This expansion is driven by the increasing prevalence of diabetes, the role of these inhibitors in managing cardiovascular risk factors, and their potential use in treating COVID-19 complications in diabetic patients. Technological advancements in drug formulations and delivery have further contributed to the market's growth trajectory. The market's resilience during the COVID-19 pandemic, supported by the commitment of pharmaceutical companies to ensure continuous supply to vulnerable populations, underscores its robust outlook.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research SGLT2 Inhibitors Market Market Size

Market Size of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Industry

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 11.42 Billion
Market Size (2029) USD 17.32 Billion
CAGR (2024 - 2029) 8.68 %
Fastest Growing Market Middle East and North Africa
Largest Market North America

Major Players

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Major Players

*Disclaimer: Major Players sorted in no particular order

SGLT2 Inhibitors Market Analysis

The Sodium-dependent Glucose Co-transporter 2 Market size is estimated at USD 11.42 billion in 2024, and is expected to reach USD 17.32 billion by 2029, growing at a CAGR of 8.68% during the forecast period (2024-2029).

The Sodium-Dependent Glucose Cotransporter 2 market benefited from the COVID-19 pandemic. People with diabetes have a weakened immune system, which is exacerbated by COVID-19. Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. 

"Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," NovoNordisk stated on their website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."

SGLT-2 inhibitors, commonly known as gliflozins, are a kind of medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors have an important role in the management of cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and antiinflammatory action. Diabetic medications have been proposed as prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 epidemic. Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed.

Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

SGLT2 Inhibitors Industry Segmentation

A family of glucose transporters is known as sodium-dependent glucose co-transporters (also known as sodium-glucose linked transporters or SGLT2). Only the proximal renal tubules express it, which is responsible for 90% of glucose reabsorption from tubular fluid. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. 

Drug
Sodium - Glucose Co-transport -2 (SGLT-2) Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States
Canada
Rest of North America
Europe
France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Asia-Pacific
Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle-East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle-East and Africa
Need A Different Region Or Segment?
Customize Now

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Size Summary

The Sodium-dependent Glucose Co-transporter 2 (SGLT2) inhibitors market is poised for significant growth, driven by the increasing prevalence of Type 2 diabetes and the rising demand for effective diabetes management solutions. These medications, also known as gliflozins, play a crucial role in controlling blood glucose levels and managing cardiovascular risk factors such as blood pressure and weight. The market has seen a positive impact from the COVID-19 pandemic, as individuals with diabetes are more susceptible to severe complications from the virus, prompting a sustained demand for diabetic medications. Technological advancements have further enhanced the formulations and efficacy of SGLT2 inhibitors, contributing to their growing adoption. Jardiance, a leading drug in this category, has gained substantial market share due to its cardiovascular benefits and effectiveness in reducing blood sugar levels.

North America, particularly the United States, represents a significant portion of the SGLT2 inhibitors market, attributed to the high prevalence of Type 2 diabetes and obesity in the region. The U.S. market is characterized by high drug prices and a robust insurance system that supports prescription drug reimbursement, making it a lucrative market for pharmaceutical companies. The market is highly consolidated, with major players like Janssen Pharmaceuticals, Eli Lilly, and AstraZeneca Pharmaceuticals dominating the landscape. Recent regulatory approvals, such as those for Jardiance and Synjardy, have expanded the market's reach, including pediatric applications and additional indications for heart failure management. These developments underscore the dynamic nature of the SGLT2 inhibitors market and its potential for continued expansion over the forecast period.

Explore More

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Sodium - Glucose Co-transport -2 (SGLT-2) Inhibitor

        1. 2.1.1.1 Invokana (Canagliflozin)

        2. 2.1.1.2 Jardiance (Empagliflozin)

        3. 2.1.1.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.1.4 Suglat (Ipragliflozin)

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Rest of North America

      2. 2.2.2 Europe

        1. 2.2.2.1 France

        2. 2.2.2.2 Germany

        3. 2.2.2.3 Italy

        4. 2.2.2.4 Spain

        5. 2.2.2.5 United Kingdom

        6. 2.2.2.6 Russia

        7. 2.2.2.7 Rest of Europe

      3. 2.2.3 Latin America

        1. 2.2.3.1 Mexico

        2. 2.2.3.2 Brazil

        3. 2.2.3.3 Rest of Latin America

      4. 2.2.4 Asia-Pacific

        1. 2.2.4.1 Japan

        2. 2.2.4.2 South Korea

        3. 2.2.4.3 China

        4. 2.2.4.4 India

        5. 2.2.4.5 Australia

        6. 2.2.4.6 Vietnam

        7. 2.2.4.7 Malaysia

        8. 2.2.4.8 Indonesia

        9. 2.2.4.9 Philippines

        10. 2.2.4.10 Thailand

        11. 2.2.4.11 Rest of Asia-Pacific

      5. 2.2.5 Middle-East and Africa

        1. 2.2.5.1 Saudi Arabia

        2. 2.2.5.2 Iran

        3. 2.2.5.3 Egypt

        4. 2.2.5.4 Oman

        5. 2.2.5.5 South Africa

        6. 2.2.5.6 Rest of Middle-East and Africa

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Size FAQs

The Sodium-dependent Glucose Co-transporter 2 Market size is expected to reach USD 11.42 billion in 2024 and grow at a CAGR of 8.68% to reach USD 17.32 billion by 2029.

In 2024, the Sodium-dependent Glucose Co-transporter 2 Market size is expected to reach USD 11.42 billion.

SGLT2 Drugs Market Report Snapshots

SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)